¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"plasma iron turnover rate"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • crude birth rate
    º¸ÅëÃâ»ý·ü, Á¶Ãâ»ý·ü
  • crude death rate
    º¸Åë»ç¸Á·ü, Á¶»ç¸Á·ü
  • crude fertility rate
    º¸Åë»ý½Ä·ü, Á¶»ý½Ä·ü
  • crude natural increase rate
    º¸ÅëÀÚ¿¬Áõ°¡À², Á¶ÀÚ¿¬Áõ°¡À²
  • crude survival rate
    º¸Åë»ýÁ¸À², Á¶»ýÁ¸À²
  • cumulative death rate
    ´©Àû»ç¸Á·ü
  • cumulative incidence rate
    ´©Àû¹ß»ý·ü
  • cumulative survival rate
    ´©Àû»ýÁ¸À²
  • cure rate
    Ä¡À¯À²
  • case fatality rate
    Áõ·ÊÄ¡¸í·ü
  • case morbidity rate
    Áõ·ÊÀÌȯÀ²
  • cause-specific rate
    ¿øÀκ°ºñÀ²
  • cerebral metabolic rate
    ³ú´ë»çÀ²
  • child death rate
    ¼Ò¾Æ»ç¸Á·ü
  • defect rate
    °áÇÔ·ü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • cardiac rate
    (¢¡heart rate) ½ÉÀå¹Úµ¿¼ö
  • case fatality rate
    Ä¡¸í·ü
  • case morbidity rate
    Áõ·ÊÀÌȯÀ²
  • cause-specific rate
    ¿øÀκ°Æ¯¼öÀ²
  • cerebral metabolic rate
    ³ú´ë»çÀ²
  • child death rate
    À¯¾Æ»ç¸Á·ü
  • completion rate
    ¿Ï¼º·ü
  • concordance rate
    ÀÏÄ¡À²
  • conversion rate
    ÀüȯÀ²
  • corrected death rate
    Á¤Á¤»ç¸Á·ü
  • corrected life birth rate
    Á¤Á¤Ãâ»ý·ü
  • crude birth rate
    Á¶Ãâ»ý·ü
  • crude death rate
    º¸Åë»ç¸Á·ü, Á¶»ç¸Á·ü
  • crude fertility rate
    Á¶»ý½Ä·ü, Á¶¼öÅÂÀ²
  • crude natural increase rate
    Á¶ÀÚ¿¬Áõ°¡À², º¸ÅëÀÚ¿¬Áõ°¡À²
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • prevalence rate
    À¯º´·ü(ËôËÓËô).
  • production rate
    »ý»êÀ²
  • puerperal death rate
    »ê¿å»ç¸Á·ü (ÊÙË×ËÎËô).
  • puerperal death rate
    »êÈÄ»ç¸Á·ü,»ê¿å»ç¸Á·ü (¡­ÞÝØÌëÒ)
  • pulse rate
    ÆÞ½ºÀ²
  • pulse repetition rate
    ÆÞ½º ¹Ýº¹À²
  • rate
    ¼Óµµ
  • rate dependent bundle branch block
    ½É¹Ú¼öÀÇÁ¸¼º °¢Â÷´Ü.
  • rate limiting
    ¼ÓµµÁ¦ÇÑÀÇ.
  • rate limiting enzyme
    ¼ÓµµÁ¶ÀýÈ¿¼Ò(áÜöôðàï½ý£áÈ).
  • rate limiting reaction
    ¼ÓµµÁ¦ÇѹÝÀÀ.
  • rate meter
    °è¼öÀ²°è(ͪâ¦ëÒͪ).
  • rate of flow
    ¹æ¼ö·ù·®, ¹æ¼ö»ý»ê·®
  • rate of hardening
    °æÈ­¼Óµµ(ÌãûùáÜöô).
  • rate of polymerization
    ÁßÇÕ·ü(ñìùêëÒ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • total iron binding capacity
    ÃÑö°áÇÕ´É
  • total iron binding capacity=TIBC
    ÃÑö°áÇÕ´É
  • total red cell iron
    Àü<ÃÑ>ÀûÇ÷±¸Ã¶(îï<õÅ>îå úìϹôÑ).
  • triple sugar iron (TSI) agar
    »ï´çûºÐ¹èÁö, TSI Àå³»¼¼±Õµ¿Á¤¹èÁö
  • triple sugar iron agar
    »ï´çöÇÑõ
  • unsaturated iron binding capacity
    ºÒÆ÷ȭö°áÇÕ´É(¡­ôÑÌ¿ùêÒö).
  • unsaturated iron binding capacity
    ºÒÆ÷ȭö°áÇÕ´É
  • wrought iron
    ¿¬Ã¶(æçôÑ).
  • antihemophilic plasma
    Ç×Ç÷¿ìº´Ç÷Àå (¡­úìíì).
  • antihemophilic plasma
    Ç×Ç÷¿ìº´Ç÷Àå (?Ì´Ëö).
  • blood plasma
    Ç÷Àå
  • blood plasma substitute
    ´ë¿ë(ÓÛéÄ)Ç÷Àå.
  • citrated normal human plasma
    Á¤»óÀα¸¿¬»ê¿°Ã·°¡Ç÷Àå.
  • coagulase plasma
    ÄھƱֶóÁ¦ Ç÷Àå
  • effective renal plasma flow
    À¯È¿½ÅÇ÷ÀåÀ¯Åë·®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MR Maddox rods; magnetic resistance; magnetic resonance; mandibular reflex; mannose-resistant; may repe...
RR radiation reaction; radiation response; rate ratio; rational recovery [group]; recovery room; relati...
PID   1) Pelvic Inflammatory Disease; °ñ¹Ý ¿°Áõ¼º Áúȯ [Chap 89, HP 534-8]
  2) Plasma I...
PID pain intensity difference [score]; pelvic inflammatory disease; photoionization detector; picture im...
PIDT plasma iron disappearance time
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
NTBI Non-transferrin-bound iron
TIBC S-total iron binding capacity
SI Serum Iron
SPIO Superparamagnetic iron oxide
USPIO Ultrasmall superparamagnetic iron oxide
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • metabolic rate
    ´ë»çÀ²
  • mortality rate
    »ç¸Á·ü
  • mutation rate
    º¯ÀÌÀ², µ¹¿¬º¯ÀÌÀ²
  • neonatal mortality rate
    ½Å»ý¾Æ »ç¸Á·ü
  • operative mortality rate
    ¼ö¼ú »ç¸Á·ü
  • overall rate
    ÃÑüÀû ºñÀ²
  • peak flow rate
    ÃÖ´ë À¯¼Ó, ÃÖ°í À¯¼Ó
  • prevalance rate
    À¯º´À²
  • prevalence rate
    À¯º´·ü
  • processing rate
    ½Ã¼ú È¿À²
  • rate dependent bundle branch block
    ½É¹Ú ¼ö ÀÇÁ¸¼º °¢ Â÷´Ü
  • rate of ablation
    Á¦°ÅÀ²
  • rate of polymerization
    ÁßÇÕ·ü
  • rate of teeth decayed
    ¿ì½Ä·ü
  • rate-limiting enzyme
    ¼Óµµ Á¶Àý È¿¼Ò
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
blood plasma fractions Portions of the blood plasma as separated by electrophoresis or other technique.
(05 Mar 2000)
rapid plasma reagin <investigation> The rapid plasma reagin test is similar to the VDRL test for diagnosing syphilis. This blood test is designed to detect an antibody substance in the bloodstream when syphilis infection is present. Early syphilis infections may be RPR negative.
See: VDRL
(17 Dec 1997)
rapid plasma reagin test A group of serologic test's for syphilis in which unheated serum or plasma is reacted with a standard test antigen containing charcoal particles; positive test's yield a flocculation. A modification, called the RPR (circle) card test, is widely used as a screening test.
Synonym: RPR test.
(05 Mar 2000)
renal plasma flow <physiology> The amount of plasma that perfuses the kidneys per unit time, approximately 10% greater than effective renal plasma flow.
It should be differentiated from the renal blood flow which refers to the total volume of blood flowing through the renal vasculature, while the renal plasma flow refers to the rate of plasma flow.
(12 Dec 1998)
peak plasma drug concentration <pharmacology> The highest level of drug that can be obtained in the blood usually following multiple doses.
(09 Oct 1997)
granuloma, plasma cell A slow-growing benign pseudotumour in which plasma cells greatly outnumber the inflammatory cells.
(12 Dec 1998)
granuloma, plasma cell, orbital A distinctive, chronic inflammatory reaction in the orbital tissues of the eye, of unknown aetiology, that may closely resemble a neoplasm and often becomes bilateral. Symptoms include exophthalmos and congestion of the lids with oedema. When limitation of ocular motility also occurs, it is sometimes called orbital myositis.
(12 Dec 1998)
granuloma, plasma cell, pulmonary A pseudotumour of the lung composed of inflammatory cells and showing complete maturity of fibroblastic components with a striking lack of mitosis. It is also called postinflammatory pseudotumour and pseudoneoplastic pneumonitis. (berardi, r.s. Et al. Inflammatory pseudotumours of the lung. Surg gynecol obstet 156:89-96, jan 83)
(12 Dec 1998)
collisionless plasma model <radiobiology> Model of a plasma in which the density is so low, or the temperature so high, that close binary (two-body) collisions have practically no significance (on certain timescales) because the time scales of interest are shorter than the collision time. Yields valid physical results for timescales much shorter than the average collision time in a real plasma.
(09 Oct 1997)
plasma <haematology> Acellular fluid in which blood cells are suspended. Serum obtained by defibrinating plasma (plasma derived serum) lacks platelet released factors and is less suitable to support the growth of cells in culture.
(13 Oct 1997)
plasma accelerator globulin <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease.
Chemical name: Blood-coagulation factor V
(12 Dec 1998)
plasma albumin <protein> The serum level of the low molecular protein albumin. Albumin, produced by the liver, plays an important role in maintaining plasma oncotic pressure. Normal serum albumin should be 3.5-5.0 grams per decilitre. Low serum albumin can be found in cases of liver disease and malnutrition.
(27 Sep 1997)
plasma cell <haematology> A terminally differentiated antibody forming and usually antibody secreting, cell of the B-cell lineage.
(18 Nov 1997)
plasma cell balanitis Benign circumscribed balanitis characterised microscopically by subepithelial plasma cell infiltration and clinically by small erythematous papular lesions.
Synonym: balanitis circumscripta plasmacellularis, balanitis of Zoon, Zoon's erythroplasia.
(05 Mar 2000)
plasma cell dyscrasia A diverse group of diseases characterised by the proliferation of a single clone of cells producing a monoclonal immunoglobulin or immunoglobulin fragment (a serum M component). The cells usually have plasma cell morphology, but may have lymphocytic or lymphoplasmacytic morphology. This group includes multiple myeloma, Waldenstrom's macroglobulinaemia, the heavy chain disease, benign monoclonal gammopathy, and immunocytic amyloidosis.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • curling iron
    Çì¾î ¾ÆÀ̾ð !
  • driving iron
    (°ñÇÁ)¾ÆÀ̾ð Ŭ·´ No.1
  • dumb iron
    (ÀÚµ¿Â÷ÀÇ)½ºÇÁ¸µ ¹Þħ
  • firing iron
    ³«Ã¶;¼Ò¶ôħ
  • foundry iron
    ÁÖö
  • galvanized iron
    ¾Æ¿¬ öÆÇ(¾çö)µî
  • grappling iron(hook)
    (Àû¼± µîÀ» °É¾î Àâ¾Æ´ç±â´Â)¼è°¥°í¸®
  • hoop iron
    (Åë µîÀÇ) ¼èÅ×
  • iron
    ¼èÀÇ;¼è °°Àº;öÁ¦ÀÇ;°ß°íÇÑ;³ÃȤÇÑ
  • iron
    ö;¼è(±Ý¼Ó¿ø¼Ò);öÁ¦ ±â±¸;¾ÆÀ̾ð;´Ù¸®¹Ì;ÀεÎ;(°ñÇÁ)¼è¸Ó¸®°¡ ´Ù¸° °ñÇÁä;µîÀÚ;Á·¼â;¼ö°©;´Ù¸®±³Á¤±â;öÁ¦;öºÐ;ÀÚµ¿Â÷;±ÇÃÑ;ÃÑ;ÀÛ»ì;ÀºÈ­
  • iron
    ´Ù¸²ÁúÇÏ´Ù;...¿¡ ¼ö°©À»(Â÷²¿¸¦) ä¿ì´Ù;¼è·Î µ¤¾î ½Î´Ù;Àå°©ÇÏ´Ù
  • iron age
    ö±â½Ã´ë;(±×½Å)ÈæÃ¶½Ã´ë(golden,age,silver age,bronze age¿¡ °è¼ÓµÇ´Â °¡Àå Ÿ¶ôÇß´ø ½Ã´ë)
  • iron crutain
    öÀÇ À帷(¼Ò·ÃÃø°ú ¼­¹æÃøÀ» °¥¶ó ³õ´Â Á¤Ä¡Àû »ç»óÀû º®(cf.BAMBOO CURTAIN
  • iron founder
    ÁÖö Á¦Á¶¾÷ÀÚ
  • iron foundry
    ÁÖö °øÀå
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á